The Japan Home vs. Office blood pressure Measurement Evaluation with CAndesartan and Restricted dose of Diuretic <J-HOME-CARD>
Phase 4
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000003356
- Lead Sponsor
- J-HOME-CARD Study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria 1) Secondary hypertension 2) Cardiac failure (above NYHA grade III) 3) Past history of major cardiac events or intervention (e.g., myocardial infarction, stroke) within 6 months prior to the start of the study. 4) Pregnancy (positive urine pregnancy test at pre-study) or breast feeding, or a female expecting to conceive within the study. 5) Critical liver damage 6) History of severe hepatic or renal disease (sCr>2.0 mg/dl) 7) Uncontrollable arrhythmia (atrial fibrillation, etc) 8) Hypersensitivity to ARB 9) Hypersensitivity to components of thiazide or similar compounds 10)Patient ineligible to this study due to other medical reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of home morning systolic blood pressure reduction between two groups during eight-week treatment.
- Secondary Outcome Measures
Name Time Method 1) Differences of home blood pressure reduction and differences of proportion achievement for target blood pressure level between two groups during eight-week treatment. 2) Differences of reduction in home nocturnal blood pressure during sleep between two groups during eight-week treatment. 3) Differences of clinic blood pressure reduction and differences of proportion achievement for target blood pressure level between two groups during eight-week treatment. 4) Differences of change in eGFR between two groups during eight-week treatment. 5) Differences of change in central blood pressure and augmentation index between two groups during eight-week treatment. 6) Changes in laboratory test results including LDL-C, K, sCr, uric acid, blood sugar, and HbA1c.